Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ANAB

ANAB - AnaptysBio Inc Stock Price, Fair Value and News

23.78USD-0.47 (-1.94%)Market Closed

Market Summary

ANAB
USD23.78-0.47
Market Closed
-1.94%

ANAB Stock Price

View Fullscreen

ANAB RSI Chart

ANAB Valuation

Market Cap

662.5M

Price/Earnings (Trailing)

-4.06

Price/Sales (Trailing)

30.95

EV/EBITDA

-3.74

Price/Free Cashflow

-4.94

ANAB Price/Sales (Trailing)

ANAB Profitability

EBT Margin

-764.38%

Return on Equity

-341.79%

Return on Assets

-40.24%

Free Cashflow Yield

-20.25%

ANAB Fundamentals

ANAB Revenue

Revenue (TTM)

21.4M

Rev. Growth (Yr)

422.49%

Rev. Growth (Qtr)

52.1%

ANAB Earnings

Earnings (TTM)

-163.3M

Earnings Growth (Yr)

0.72%

Earnings Growth (Qtr)

-4.09%

Breaking Down ANAB Revenue

Last 7 days

1.6%

Last 30 days

-3.8%

Last 90 days

3.6%

Trailing 12 Months

30.9%

How does ANAB drawdown profile look like?

ANAB Financial Health

Current Ratio

11.53

ANAB Investor Care

Shares Dilution (1Y)

3.14%

Diluted EPS (TTM)

-6.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202421.4M000
202311.3M14.9M17.5M15.6M
202250.0M36.7M23.5M10.3M
202171.2M101.3M122.2M63.2M
202023.0M18.0M18.0M75.0M
201907.5M10.0M8.0M
2018003.3M5.0M
2017018.8M13.0M1.6M
201617.3M17.1M16.9M16.7M
201500017.6M

Tracking the Latest Insider Buys and Sells of AnaptysBio Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 22, 2024
mulroy dennis
sold
-35,580
23.72
-1,500
chief financial officer
Mar 26, 2024
faga daniel
sold (taxes)
-7,504,730
21.6
-347,441
ceo
Mar 25, 2024
faga daniel
sold
-64,267
21.4225
-3,000
ceo
Mar 22, 2024
faga daniel
sold
-3,325,180
22.7846
-145,940
ceo
Feb 16, 2024
loumeau eric j
acquired
70,100
14.02
5,000
chief legal officer
Feb 16, 2024
loumeau eric j
sold
-125,000
25.00
-5,000
chief legal officer
Jan 30, 2024
mulroy dennis
sold
-72,425
23.6298
-3,065
chief financial officer
Jan 08, 2024
loumeau eric j
sold
-50,272
21.81
-2,305
chief legal officer
Jan 08, 2024
mulroy dennis
sold
-47,545
21.81
-2,180
chief financial officer
Jan 08, 2024
faga daniel
sold
-149,747
21.81
-6,866
ceo

1–10 of 50

Which funds bought or sold ANAB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.76
49,370
115,370
0.01%
May 20, 2024
Virtu Financial LLC
new
-
222,000
222,000
0.02%
May 16, 2024
JANE STREET GROUP, LLC
added
28.5
226,362
871,254
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-23.09
-61,006
257,809
-%
May 15, 2024
Caption Management, LLC
sold off
-100
-364,226
-
-%
May 15, 2024
Virtus ETF Advisers LLC
reduced
-6.4
-1,655
102,489
0.05%
May 15, 2024
TWO SIGMA INVESTMENTS, LP
added
37.06
826,854
2,701,750
0.01%
May 15, 2024
Aquatic Capital Management LLC
new
-
171,152
171,152
0.01%
May 15, 2024
Squarepoint Ops LLC
reduced
-34.9
-121,170
262,741
-%
May 15, 2024
TANG CAPITAL MANAGEMENT LLC
reduced
-31.77
-11,810,600
29,971,400
3.12%

1–10 of 45

Are Funds Buying or Selling ANAB?

Are funds buying ANAB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ANAB
No. of Funds

Unveiling AnaptysBio Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 06, 2024
frazier life sciences public fund, l.p.
2.2%
611,746
SC 13G
Feb 14, 2024
deep track capital, lp
7.67%
2,036,990
SC 13G/A
Feb 14, 2024
point72 asset management, l.p.
3.0%
788,545
SC 13G/A
Feb 14, 2024
tang capital partners lp
7.3%
1,950,609
SC 13G/A
Feb 13, 2024
vanguard group inc
5.19%
1,380,115
SC 13G/A
Jan 26, 2024
blackrock inc.
6.8%
1,799,823
SC 13G/A
Oct 02, 2023
deep track capital, lp
5.12%
1,360,176
SC 13G
Feb 14, 2023
point72 asset management, l.p.
7.5%
2,124,200
SC 13G/A
Feb 10, 2023
flynn james e
4.09%
1,161,826
SC 13G/A
Feb 09, 2023
federated hermes, inc.
4.93%
1,401,559
SC 13G/A

Recent SEC filings of AnaptysBio Inc

View All Filings
Date Filed Form Type Document
Jun 12, 2024
8-K
Current Report
May 24, 2024
4
Insider Trading
May 09, 2024
8-K
Current Report
May 09, 2024
10-Q
Quarterly Report
May 06, 2024
SC 13G
Major Ownership Report
Apr 24, 2024
DEFA14A
DEFA14A
Apr 24, 2024
DEF 14A
DEF 14A
Apr 24, 2024
ARS
ARS
Mar 26, 2024
4
Insider Trading
Mar 11, 2024
S-8
Employee Benefits Plan

Peers (Alternatives to AnaptysBio Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.96
10.11
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.85
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.88
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.86
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.06
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

AnaptysBio Inc News

Latest updates
MarketBeat29 hours ago

AnaptysBio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Revenue52.1%7,179,0004,720,0004,854,0004,653,0001,374,0006,576,0002,262,0001,107,0001,059,0001,011,00020,890,00030,027,00011,247,00060,000,000--15,000,0003,000,000-5,000,000-
Operating Expenses-3.4%49,380,00051,140,00041,050,00043,603,00045,775,00032,781,00030,926,00029,015,00032,719,00032,168,00027,653,00030,560,00029,608,00026,655,00024,336,00022,635,00025,253,00025,258,00033,745,00031,657,00019,663,000
  S&GA Expenses20.1%12,338,00010,276,00010,172,00010,680,00010,818,0009,407,0008,862,0008,171,00010,203,0005,392,0005,432,0005,246,0005,423,0005,088,0004,794,0004,687,0004,285,0003,832,0003,814,0004,307,0003,743,000
  R&D Expenses-37,042,000-30,878,00032,923,00034,957,00023,374,00022,064,00020,844,00022,516,00026,776,00022,221,00025,314,00024,185,00021,567,00019,542,00017,948,00020,968,00021,426,00029,931,00027,350,00015,920,000
EBITDA Margin27.1%-7.61-10.45-6.22-7.12-8.87-12.45-2.43-1.56-1.14-0.91-0.16-0.19---------
Interest Expenses-----------------4,000200,000240,000281,000365,000
Income Taxes-------------------22,000-51,000-60,000-192,000
Earnings Before Taxes--------------33,646,000-23,767,000-21,548,000-8,262,000-20,285,000-31,084,000-24,022,000-17,186,000
EBT Margin27.1%-7.64-10.49-6.26-7.16-8.92-12.51-2.46-1.57-1.16-0.91-0.16-0.20---------
Net Income-4.1%-43,936,000-42,211,000-37,308,000-39,845,000-44,255,000-26,413,000-33,502,000-32,554,000-36,255,000-32,538,000-6,666,000-429,000-18,163,00033,646,000-23,767,000-21,548,000-8,262,000-20,263,000-31,033,000-23,962,000-16,994,000
Net Income Margin27.3%-7.63-10.49-7.19-8.01-9.47-12.51-5.74-2.94-1.52-0.910.07-0.09---------
Free Cashflow-7.7%-37,280,000-34,629,000-36,636,000-25,599,000-24,743,000-10,860,000-17,797,000-24,225,000-21,069,000-25,315,000-7,178,0008,728,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-10.3%406452487517552610619604625643424427396417385402424435452480494
  Current Assets-8.5%372407428439437447450453512554387398387397346385371378425431422
    Cash Equivalents49.3%54.0036.0026.0035.0095.0071.0059.0072.00166496336332284251209221165171183147106
  Net PPE-6.9%2.002.002.002.002.002.002.002.002.002.002.002.002.002.002.001.002.002.002.001.002.00
  Current Liabilities-13.7%32.0037.0039.0042.0036.0026.0021.0020.0020.0016.0021.0021.0014.0020.0024.0020.0023.0030.0030.0031.0025.00
Shareholder's Equity-45.8%48.0088.00120148191262278304331356384386382397360381401405421448468
  Retained Earnings-7.2%-658-614-571-534-494-450-424-390-358-321-289-282-282-263-297-273-252-244-223-192-168
  Additional Paid-In Capital0.5%706703695687689718708699691679673668664661658654652649644641637
Shares Outstanding2.7%27.0027.0027.0027.0028.0029.0028.0028.0028.0027.0027.0027.00---------
Float----367---400---489---556---1,391-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-8.5%-37,253-34,349-36,474-25,409-24,568-10,685-17,747-24,147-21,014-25,301-7,0069,591-23,20437,578-17,013-19,610-15,112-15,805-22,096-15,517-16,099
  Share Based Compensation-23.7%10,13113,2783,0002,9008,86010,2003,0002,9007,7423,9784,3643,6903,315--------
Cashflow From Investing39.5%68,61649,17830,635-20,45585,39621,497-32,434-70,996-312,912-66,69410,83937,96156,7293,5984,73275,39410,7514,03559,86357,8769,657
Cashflow From Financing-164.3%-13,633-5,159-3,072-13,492-37,5741,94937,0274324,609251,33624155416712626371.00-1,339-111-1,421-1,660-1,301
  Buy Backs-100.0%-416-13.0011,65637,526----------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ANAB Income Statement

2024-03-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]Collaboration Revenue [Member]Collaboration Revenue [Member]
Collaboration revenue$ 7,179$ 1,374
Operating expenses:  
Research and development37,04234,957
General and administrative12,33810,818
Total operating expenses49,38045,775
Loss from operations(42,201)(44,401)
Other (expense) income, net:  
Interest income4,5844,486
Non-cash interest expense for the sale of future royalties(6,317)(4,336)
Other expense, net(2)(4)
Total other (expense) income, net(1,735)146
Net loss(43,936)(44,255)
Unrealized gain on available for sale securities1731,979
Comprehensive loss$ (43,763)$ (42,276)
Net loss per common share:  
Basic (in dollars per share)$ (1.64)$ (1.58)
Diluted (in dollars per share)$ (1.64)$ (1.58)
Weighted-average number of shares outstanding:  
Basic (in shares)26,80127,953
Diluted (in shares)26,80127,953

ANAB Balance Sheet

2024-03-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 53,695$ 35,965
Receivables from collaborative partners7,0896,851
Short-term investments300,970354,939
Prepaid expenses and other current assets10,6669,080
Total current assets372,420406,835
Property and equipment, net1,9542,098
Operating lease right-of-use assets15,73216,174
Long-term investments15,47327,026
Other long-term assets256256
Total assets405,835452,389
Current liabilities:  
Accounts payable4,5824,698
Accrued expenses25,90330,967
Current portion of operating lease liability1,8131,777
Total current liabilities32,29837,442
Liability related to sale of future royalties310,184310,807
Operating lease liability, net of current portion15,57516,037
Stockholders’ equity:  
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at March 31, 2024 and December 31, 2023, respectively00
Common stock, $0.001 par value, 500,000 shares authorized, 27,317 shares and 26,597 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively2727
Additional paid in capital706,407702,969
Accumulated other comprehensive loss(624)(797)
Accumulated deficit(658,032)(614,096)
Total stockholders’ equity47,77888,103
Total liabilities and stockholders’ equity$ 405,835$ 452,389
ANAB
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
 CEO
 WEBSITEanaptysbio.com
 INDUSTRYBiotechnology
 EMPLOYEES96

AnaptysBio Inc Frequently Asked Questions


What is the ticker symbol for AnaptysBio Inc? What does ANAB stand for in stocks?

ANAB is the stock ticker symbol of AnaptysBio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AnaptysBio Inc (ANAB)?

As of Thu Jun 13 2024, market cap of AnaptysBio Inc is 662.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANAB stock?

You can check ANAB's fair value in chart for subscribers.

What is the fair value of ANAB stock?

You can check ANAB's fair value in chart for subscribers. The fair value of AnaptysBio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AnaptysBio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANAB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AnaptysBio Inc a good stock to buy?

The fair value guage provides a quick view whether ANAB is over valued or under valued. Whether AnaptysBio Inc is cheap or expensive depends on the assumptions which impact AnaptysBio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANAB.

What is AnaptysBio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, ANAB's PE ratio (Price to Earnings) is -4.06 and Price to Sales (PS) ratio is 30.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANAB PE ratio will change depending on the future growth rate expectations of investors.